


MEDICAL POLICY	Diabetes: Blood Glucose Monitor and Supplies (Medicare Only)	
Effective Date: 9/1/2020  <div style="text-align: right;">9/1/2020</div>	Section: DME	Policy No: 421
	Medical Policy Committee Approved Date: 8/2020;	
Medical Officer	Date	

See Policy CPT/HCPCS CODE section below for any prior authorization requirements

SCOPE:

Providence Health Plan, Providence Health Assurance, Providence Plan Partners, and Ayin Health Solutions as applicable (referred to individually as “Company” and collectively as “Companies”).

APPLIES TO:

Medicare Only

MEDICARE POLICY CRITERIA

The following Centers for Medicare & Medicaid Service (CMS) guidelines should be utilized for medical necessity coverage determinations. Click the link provided in the table below to access applicable medical necessity criteria. All listed guidelines apply.

Note: Blood glucose test or reagent strips (A4253) are addressed in the Providence Health Plan Pharmacy policy: Miscellaneous Products, Blood Glucose Test Strips.

Service	Medicare Guidelines
<i>Home blood glucose monitors and related accessories and supplies</i>	<ul style="list-style-type: none"> Local Coverage Determination (LCD): Glucose Monitors (L33822)¹ Local Coverage Article: Glucose Monitor – Policy Article (A52464)²

BILLING GUIDELINES

For DMEPOS provided on a recurring basis, billing must be based on prospective, not retrospective use. For DMEPOS products (A4233-A4236, A4256, A4258 and A4259) that are supplied as refills to the original order, suppliers must contact the beneficiary prior to dispensing the refill and not automatically ship on a pre-determined basis, even if authorized by the beneficiary. This shall be done to ensure that the refilled item remains reasonable and necessary, existing supplies are approaching exhaustion, and to

MEDICAL POLICY	Diabetes: Blood Glucose Monitor and Supplies (Medicare Only)
-----------------------	---

confirm any changes or modifications to the order. Contact with the beneficiary or designee regarding refills must take place no sooner than 14 calendar days prior to the delivery/shipping date. For delivery of refills, the supplier must deliver the DMEPOS product no sooner than 10 calendar days prior to the end of usage for the current product. This is regardless of which delivery method is utilized. (CMS Program Integrity Manual, Internet-Only Manual, CMS Pub. 100-08, Chapter 5, Section 5.2.6).

For all DMEPOS items that are provided on a recurring basis, suppliers are required to have contact with the beneficiary or caregiver/designee prior to dispensing a new supply of items. Suppliers must not deliver refills without a refill request from a beneficiary. Items delivered without a valid, documented refill request will be denied as not reasonable and necessary.

Suppliers must not dispense a quantity of supplies exceeding a beneficiary's expected utilization. Suppliers must stay attuned to changed or atypical utilization patterns on the part of their clients. Suppliers must verify with the ordering physicians that any changed or atypical utilization is warranted. Regardless of utilization, a supplier must not dispense more than a three (3)-month quantity at a time.

See Providence Health Plan Pharmacy Operational Policy: Miscellaneous Products, Blood Glucose Test Strips regarding glucose test or reagent strips.

CPT/HCPCS CODES

Medicare Only	
No Prior Authorization Required	
Blood Glucose Monitors:	
E0607	Home blood glucose monitor
E2100	Blood glucose monitor with integrated voice synthesizer
E2101	Blood glucose monitor with integrated lancing/blood sample
Glucose Supplies	
A4206	Syringe with needle, sterile, 1 cc or less, each
A4215	Needle, sterile, any size, each
A4233	Replacement battery, alkaline (other than j cell), for use with medically necessary home blood glucose monitor owned by patient, each
A4234	Replacement battery, alkaline, j cell, for use with medically necessary home blood glucose monitor owned by patient, each
A4235	Replacement battery, lithium, for use with medically necessary home blood glucose monitor owned by patient, each
A4236	Replacement battery, silver oxide, for use with medically necessary home blood glucose monitor owned by patient, each
A4255	Platforms for home blood glucose monitor, 50 per box
A4258	Spring-powered device for lancet, each
A4259	Lancets, per box of 100
S8490	Insulin syringes (100 syringes, any size)

MEDICAL POLICY	Diabetes: Blood Glucose Monitor and Supplies (Medicare Only)
-----------------------	---

Not Covered	
Glucose Supplies	
A4244	Alcohol or peroxide, per pint
A4245	Alcohol wipes, per box
A4246	Betadine or phisohex solution, per pint
A4247	Betadine or iodine swabs/wipes, per box
A4250	Urine test or reagent strips or tablets (100 tablets or strips)
A4257	Replacement lens shield cartridge for use with laser skin piercing device, each
A9270	Non-covered item or service
A9275	Home glucose disposable monitor, includes test strips
E0620	Skin piercing device for collection of capillary blood, laser, each

INSTRUCTIONS FOR USE

Company Medical Policies serve as guidance for the administration of plan benefits. Medical policies do not constitute medical advice nor a guarantee of coverage. Company Medical Policies are reviewed annually and are based upon published, peer-reviewed scientific evidence and evidence-based clinical practice guidelines that are available as of the last policy update. The Companies reserve the right to determine the application of Medical Policies and make revisions to Medical Policies at any time. Providers will be given at least 60-days notice of policy changes that are restrictive in nature.

The scope and availability of all plan benefits are determined in accordance with the applicable coverage agreement. Any conflict or variance between the terms of the coverage agreement and Company Medical Policy will be resolved in favor of the coverage agreement.

REGULATORY STATUS

Mental Health Parity Statement

Coverage decisions are made on the basis of individualized determinations of medical necessity and the experimental or investigational character of the treatment in the individual case.

REFERENCES

- Centers for Medicare & Medicaid Services. Local Coverage Determination (LCD): Glucose Monitors (L33822). <https://www.cms.gov/medicare-coverage-database/details/lcd-details.aspx?LCDId=33822>. Published 2015. Accessed 5/19/2020.
- Centers for Medicare & Medicaid Services. Local Coverage Article: Glucose Monitor - Policy Article (A52464). <https://www.cms.gov/medicare-coverage-database/details/article-details.aspx?articleId=52464>. Published 2015. Accessed 5/26/2020.